User:C Michael Gibson: Difference between revisions
No edit summary |
|||
| Line 21: | Line 21: | ||
Dr. Gibson’s work has largely focused on investigating the pathophysiology of coronary artery disease and the efficacy of pharmacologic and device based therapies. His work has been presented in over 1000 manuscripts, abstracts, trial summaries, textbooks and textbook chapters. | Dr. Gibson’s work has largely focused on investigating the pathophysiology of coronary artery disease and the efficacy of pharmacologic and device based therapies. His work has been presented in over 1000 manuscripts, abstracts, trial summaries, textbooks and textbook chapters. | ||
Over 20 years ago, Gibson founded [http://www.perfuse.org PERFUSE], an academic research organization which has served as the angiographic core laboratory and data coordinating center for a wide variety of studies including acute MI studies, unstable angina studies, interventional cardiology trials, peripheral interventional trials, venographic trials, angiogenesis trials (VEGF), imaging modality studies, managed care analyses for HCFA, and atherosclerosis regression trials such as the NIH-sponsored Harvard Atherosclerosis Reversibility Project (HARP). Gibson directed the TIMI angiographic core laboratory and invented the TIMI frame count (CTFC) in which the number of cineframes for dye to reach standardized distal landmarks is counted (an index of epicardial blood flow). Gibson also invented the TIMI myocardial perfusion grade (the blush, a measure of microvascular perfusion). The TIMI frame count and the TIMI myocardial perfusion grade are both multivariate predictors of 2 year mortality in acute MI, and are now widely used both clinically and in the assessment of new reperfusion strategies. The methods invented by Gibson and his research have played a critical role in our understanding of "the open artery hypothesis" and more recently in what Gibson has termed "the open microvasculature hypothesis". On Google scholar, the TIMI Frame Count is listed as being cited in over | Over 20 years ago, Gibson founded [http://www.perfuse.org PERFUSE], an academic research organization which has served as the angiographic core laboratory and data coordinating center for a wide variety of studies including acute MI studies, unstable angina studies, interventional cardiology trials, peripheral interventional trials, venographic trials, angiogenesis trials (VEGF), imaging modality studies, managed care analyses for HCFA, and atherosclerosis regression trials such as the NIH-sponsored Harvard Atherosclerosis Reversibility Project (HARP). Gibson directed the TIMI angiographic core laboratory and invented the TIMI frame count (CTFC) in which the number of cineframes for dye to reach standardized distal landmarks is counted (an index of epicardial blood flow). Gibson also invented the TIMI myocardial perfusion grade (the blush, a measure of microvascular perfusion). The TIMI frame count and the TIMI myocardial perfusion grade are both multivariate predictors of 2 year mortality in acute MI, and are now widely used both clinically and in the assessment of new reperfusion strategies. The methods invented by Gibson and his research have played a critical role in our understanding of "the open artery hypothesis" and more recently in what Gibson has termed "the open microvasculature hypothesis". On Google scholar, the TIMI Frame Count is listed as being cited in over 1900 articles ([http://scholar.google.com/scholar?hl=en&lr=&q=%22timi+frame+count%22&btnG=Search for updated numbers click here]) and the TIMI myocardial perfusion grade is listed as being cited in over 800 articles ([http://scholar.google.com/scholar?hl=en&q=%22timi+myocardial+perfusion+grade%22&btnG=Search for updated numbers click here]). | ||
Under Gibson's direction, [http://www.perfuse.org PERFUSE] created the master database that unified data from over 25 years of TIMI studies (TIMI 1-50) in nearly 100,000 patients and coordinated data analyses for the TIMI study group and functioned as the TIMI Data Coordinating Center. | Under Gibson's direction, [http://www.perfuse.org PERFUSE] created the master database that unified data from over 25 years of TIMI studies (TIMI 1-50) in nearly 100,000 patients and coordinated data analyses for the TIMI study group and functioned as the TIMI Data Coordinating Center. | ||
Within the Thrombolysis In Myocardial Infarction (TIMI) Study Group, Dr. Gibson has served as a Principle Investigator of multiple international trials within the TIMI Study Chairman’s Office. | Within the Thrombolysis In Myocardial Infarction (TIMI) Study Group, Dr. Gibson has served as a Principle Investigator of multiple international trials within the TIMI Study Chairman’s Office. | ||
==Textbooks== | ==Textbooks== | ||
Revision as of 15:22, 30 July 2010
C. Michael Gibson M.S., M.D., Associate Professor of Medicine, Harvard Medical School
Founder and Chairman of the Board, WikiDoc Foundation (a 509 (a)(1) Charitable Organization)
Contact: mailto:mgibson@wikidoc.org; Phone 617-632-7753
Mailing Address: C. Michael Gibson, M.S., M.D., 185 Pilgrim Road, Deaconess 319, Boston MA, 02215.
Headshot: Download large headshot here or download small headshot here
Download This Brief Bio as a Word Document: Download this brief bio as a word document here
C. Michael Gibson, M.S., M.D. is an interventional cardiologist, cardiovascular researcher and educator who pioneered our understanding of the "open artery hypothesis" as well our understanding of the importance of restoring flow downstream in the capillary bed in the "open microvasculature hypothesis". He has led his own Academic Research Organization (PERFUSE) for over 20 years now, and his work has been presented in over 1000 manuscripts, abstracts, trial summaries, textbooks and textbook chapters. He is Founder and Chairman of the Board of the non-profit WikiDoc foundation, the world's largest open source textbook of medicine.
Education and Academic Positions
Dr. Gibson received his B.S., M.S., and M.D. degrees from the University of Chicago. He was an Intern, Resident and Chief Resident at the Brigham and Women’s Hospital, Harvard Medical School. He received his training as an interventional cardiologist and served as the Director of the Coronary Care Unit at Beth Israel Hospital, Harvard Medical School. Dr. Gibson then served as the Chief of Cardiology and Director of Interventional Cardiology at the West Roxbury Veterans Affairs Medical Center, Harvard Medical School. While at the West Roxbury VA, he also served as an Associate Physician at the Brigham and Women’s Hospital. He then moved on to Allegheny General Hospital as Vice Chairman of Medicine for Clinical Research and Director of Invasive Cardiology. He subsequently relocated to the west coast and served as Associate Chief of Cardiology, Chief of Interventional Cardiology and Director of the Cardiac Catheterization Laboratory at University of California San Francisco (UCSF). In 2000, Gibson returned to Harvard Medical School in Boston. Until 2003, Dr. Gibson served as Chief Academic Officer and Director of Core Services at Harvard Clinical Research Institute (HCRI), until 2005 he served as Associate Chief of Cardiology and Director of Academic Affairs in the Cardiovascular Division at the Beth Israel Deaconess Medical Center. Until 2009 he served as the Director of the TIMI Data Coordinating Center at the Brigham and Women’s Hospital. He is currently a full time interventional cardiologist and Chief of Clinical Research in the Cardiovascular Division at Beth Israel Deaconess Medical Center, Harvard Medical School.
Research
Dr. Gibson’s work has largely focused on investigating the pathophysiology of coronary artery disease and the efficacy of pharmacologic and device based therapies. His work has been presented in over 1000 manuscripts, abstracts, trial summaries, textbooks and textbook chapters.
Over 20 years ago, Gibson founded PERFUSE, an academic research organization which has served as the angiographic core laboratory and data coordinating center for a wide variety of studies including acute MI studies, unstable angina studies, interventional cardiology trials, peripheral interventional trials, venographic trials, angiogenesis trials (VEGF), imaging modality studies, managed care analyses for HCFA, and atherosclerosis regression trials such as the NIH-sponsored Harvard Atherosclerosis Reversibility Project (HARP). Gibson directed the TIMI angiographic core laboratory and invented the TIMI frame count (CTFC) in which the number of cineframes for dye to reach standardized distal landmarks is counted (an index of epicardial blood flow). Gibson also invented the TIMI myocardial perfusion grade (the blush, a measure of microvascular perfusion). The TIMI frame count and the TIMI myocardial perfusion grade are both multivariate predictors of 2 year mortality in acute MI, and are now widely used both clinically and in the assessment of new reperfusion strategies. The methods invented by Gibson and his research have played a critical role in our understanding of "the open artery hypothesis" and more recently in what Gibson has termed "the open microvasculature hypothesis". On Google scholar, the TIMI Frame Count is listed as being cited in over 1900 articles (for updated numbers click here) and the TIMI myocardial perfusion grade is listed as being cited in over 800 articles (for updated numbers click here).
Under Gibson's direction, PERFUSE created the master database that unified data from over 25 years of TIMI studies (TIMI 1-50) in nearly 100,000 patients and coordinated data analyses for the TIMI study group and functioned as the TIMI Data Coordinating Center.
Within the Thrombolysis In Myocardial Infarction (TIMI) Study Group, Dr. Gibson has served as a Principle Investigator of multiple international trials within the TIMI Study Chairman’s Office.
Textbooks
Dr. Gibson is Founder and Chairman of the Board of WikiDoc Foundation (a 509 (a)(1) Charitable Organization). This is the world's largest medical textbook / encyclopedia. There are currently over 30,000 page views daily of over 70,000 chapters of content contributed and edited over 450,000 times by over 2,000 registered users. In 2010, WikiDoc was selected as a Google Grant recipient.
Dr. Gibson also edits a textbook entitled “Gibson's Treatment Strategies in Interventional Cardiology” which is optimized for hand held devices. In the past, Gibson has authored the chapter on Primary Angioplasty in Randomized Trials in Cardiovascular Disease published as a companion to Braunwald's Heart Disease. In the past he has co-authored the chapter “Recognition and Management of Patients with Stable Angina Pectoris" in Braunwald and Goldman’s Primary Cardiology. He has served as lead author of the section on myocardial perfusion imaging in an imaging textbook which is a companion to Braunwald’s Heart Disease. Gibson has authored the chapter “Profiles in Coronary Artery Disease” in the fifth and sixth editions of Grossman and Baim’s Textbook of Interventional Cardiology.
Editorial Boards
Dr. Gibson is on the editorial board of Circulation, the Journal of the American College of Cardiology Interventions, Cardiac Catheterization and Intervention and the American Heart Journal.
Internet Educational Sites
Dr. Gibson is Founder and Editor-in-Chief of Clinical Trial Results where he created the first weekly TV show for Cardiologists "This Week in Cardiology" and has provided slides summarizing clinical trials since 1999. Gibson also created TIMI.org, the website of the TIMI Study Group.
Awards
Gibson graduated from college Phi Beta Kappa, and from medical school Alpha Omega Alpha, both from the University of Chicago. In 1993 he was selected as the Julian and Eunice Cohen Scholar in Medicine at the Brigham and Women's Hospital.
In conjunction with delivering the opening plenary lecture at the 10th annual Great Wall of China Symposium in 2003, Gibson was awarded the Gold Medal by the Institute of Geriatric Cardiology, Chinese Peoples Liberation Army General Hospital, Beijing China for his achievements in cardiovascular science.
In 2005, the John Paul II Hospital in Krakow, Poland awarded Gibson the Pro Bono Curantium Gold Medal for Merit, and a research laboratory was named there in his honor. He was the 4th such awardee, the others being Pope John Paul II and Dr. Valentine Fuster. In that same year, Gibson was awarded the Medal of the Jagiellonian University for his outstanding achievements in education and research in cardiovascular science.
In 2009, the Cardiovascular Division of Istanbul University, Turkey, established the C. Michael Gibson Research and Education Center. In that same year, the Turkish Cardiac Society honored Gibson for establishing WikiDoc on, September 27th, World Heart Day.
In 2007 and 2009, Gibson was selected by Who's Who as the Clinical Researcher of the Year.
In 2009, Gibson was chosen by his peers as one of Boston's Top Doctors in Boston Magazine.
In 2010, Gibson was selected as one of America's Top Doctors by Castle Connolly Medical Ltd.
Gibson is an award winning fine art black and white photographer whose work has been exhibited in museums and one man gallery shows. In a juried competition, his work was selected as one of 50 artists from around the world for the 2009 Carmel Art and Film festival. His work can be viewed at f64 And More Gallery and on Flickr.
Disclosures:
Present Research/Grant Funding
Abbott; Angel Medical Corporation; Astra Zeneca; Atrium Medical Systems; Baxter; Bayer Corp. Cardica, Inc.; FibroGen, Inc.; Fold Rx; Genentech, Inc.; HeartScape Technologies; INO Therapeutics, Inc.; Johnson & Johnson Corporation; Lantheus Medical Imaging; NewCardio, Inc.; Portola Pharmaceuticals; Sanofi-Aventis; Schering Plough Corporation
Consultant and Speaking Engagements
Acusphere, Inc.; Angel Medical Systems; Archemix Corporation; Ascenta Therapeutics; Atrium Medical Corporation; Bayer Corporation; Cardica Inc.; Heartscape Technologies, Inc.; ICON Medical Imaging; Jim Moran Heart and Vascular Research Institute; Johnson & Johnson Corporation; Medicure, Inc.; Novartis Pharmaceutical Corporation; Portola Pharmaceuticals, Inc.; Sanofi-Aventis Pharmaceuticals; Schering Plough Corporation; St. Jude Medical; The Medicines Company
Royalties as a Contributor
UpToDate in Cardiovascular Medicine; Pocket Medicine
Past Research/Grant Funding/Past Speakers Bureau/Past Consulting
ActivBiotics, Inc.; Acusphere, Inc.; Ascenta Therapeutics, Inc; Astra; Atrium Medical Corporation; Bard Corporation; Biogen IDEC; Boston Scientific Corporation; Bristol Meyers Squibb Company; British Biotech, plc.; CardioKinetix, Inc.; Ciba Geigy Corporation; COR Therapeutics; Corgentech, Inc.; DVI Guidant Corporation; Eli Lilly and Company; Genentech, Inc.; GlaxoSmithKline; INO Therapeutics, LLC; KAI Pharmaceuticals; Merck & Co., Inc.; Millennium Pharmaceuticals; Momenta Pharmaceuticals; NIH; Novartis Corporation; Nuvelo; PDL Pharmaceuticals; Percusurge, Inc.; Pfizer; Point Biomedical Corporation; Portola Pharmaceuticals, Inc.; Sanofi-Aventis Corporation; Smith Kline Beecham; Sonus; St. Jude Medical; The Medicines Company; timi3 Systems, Inc.
Key words, synonyms: CM Gibson, M Gibson, C Gibson, C.M. Gibson, M. Gibson, C. Gibson, Dr. C.M. Gibson, Dr. M. Gibson, Charles Michael Gibson, Charles M. Gibson, Gibson CM, Gibson CM M.D., C. Michael Gibson M.S. M.D., Mike Gibson, Dr. Mike Gibson, Mike Gibson M.D., Dr. C. Michael Gibson, Dr. CM Gibson, Dr. Gibson, Doctor Gibson